SAN DIEGO--(BUSINESS WIRE)--Researchers from Illumina, Inc. (NASDAQ:ILMN) and the Wellcome Trust Sanger Institute have used Illumina’s next generation sequencing technology to create a draft genome sequence for the endangered Tasmanian devil, and will use this to find genetic mutations in the transmissible cancer that is ravaging its population.
